Related Experiment Video
Updated: Jun 30, 2026
09:22
Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
Published on: November 4, 2015
[Chronic thromboembolic pulmonary hypertension (CTEPH)]
1Abteilung für Kardiologie, Medizinische Universität Wien, Osterreich. irene.lang@meduniwien.ac.at
Deutsche Medizinische Wochenschrift (1946)
|October 1, 2008
Summary
Chronic thromboembolic pulmonary hypertension (CTEPH) develops in 3.8% of pulmonary embolism survivors within two years. Risk factors include prior pulmonary embolism, young age, and large perfusion deficits, with surgery offering an 80% healing rate.
Area of Science:
- Cardiovascular Medicine
- Pulmonology
- Hematology
Context:
- Venous thromboembolism (VTE) spectrum includes deep vein thrombosis and pulmonary embolism (PE).
- Pulmonary embolism can lead to severe complications like post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension (CTEPH).
- CTEPH affects approximately 3.8% of PE survivors within two years post-event.
Purpose:
- To identify risk factors for developing chronic thromboembolic pulmonary hypertension (CTEPH) after a pulmonary embolism (PE).
- To outline the diagnostic criteria and current treatment strategies for CTEPH.
- To assess the efficacy of surgical intervention for CTEPH.
Summary:
- A prospective study of 300 PE patients indicates CTEPH incidence of 3.8% within two years.
- Predictors of CTEPH include prior PE, young age, significant perfusion deficit, and idiopathic etiology.
- Diagnosis relies on perfusion scans and pulmonary hypertension; surgical endarterectomy is the primary treatment, achieving 80% functional recovery.
Impact:
- Highlights key risk factors for CTEPH, enabling targeted screening and prevention efforts.
- Emphasizes the necessity of an interdisciplinary approach for CTEPH diagnosis and management.
- Demonstrates the high success rate of surgical endarterectomy, offering significant functional improvement for CTEPH patients.
Related Concept Videos
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...